Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 7/20 | 0.38 |
| ▸ | NOS3 | P29474 | 6/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9847027 | 0.98 | NOS2 (0.37) | NOS2NOS3CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL18398543 | 0.81 | NOS2 (0.53) | NOS2NOS3CYP1A2KDM4ENOS1 | |
| SCHEMBL31214598 | 0.79 | NOS2 (0.38) | NOS2NOS3KDM4ENOS1MEN1 | |
| SCHEMBL305502 | 0.78 | NOS2 (0.45) | NOS2NOS3KDM4EALDH1A1HPGD | |
| SCHEMBL31150926 | 0.78 | NOS2 (0.45) | NOS2NOS3KDM4EALDH1A1HPGD | |
| SCHEMBL4912082 | 0.78 | NOS2 (0.56) | NOS2NOS3KDM4EALDH1A1HPGD | |
| SCHEMBL3679899 | 0.77 | KDM4E (0.47) | CYP1A2CYP2D6CYP2C19HIF1AKDM4E | |
| SCHEMBL9846961 | 0.76 | NOS2 (0.40) | NOS2NOS3CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7966532 | 0.76 | MKNK1 (0.37) | NOS2NOS3ALDH1A1DYRK1AMKNK1 | |
| SCHEMBL24813513 | 0.75 | NCF1 (0.32) | NOS2NOS3NCF1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688754-A1 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260028351-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. | 2026-01-29 | — | — | US | disclosed |
| WO-2024220626-A1 | SMALL MOLECULE MODULATORS OF OGG1 | AZKARRA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024211744-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| CN-108349960-A | New nostoc element compound and conjugate, their preparation and their therapeutical uses | 赛诺菲 | 2018-07-31 | — | — | CN | disclosed |
| EP-0435222-A2 | Aminopyridinylmethanols and aminomethylpyridinamines and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028351-A1 | KCC2 POTENTIATORS AND USES THEREOF | GRIN2C, HCN1, KCNC1 | NOS2 3832/4885NOS3 2918/4885CYP1A2 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.